CME OnDemand: 2022 AOFAS Annual Meeting-Early Revisions, Reoperation, and Survivorship of the Exactech Vantage Fixed-Bearing Total Ankle Arthroplasty Implant

Early Revisions, Reoperation, and Survivorship of the Exactech Vantage Fixed-Bearing Total Ankle Arthroplasty Implant

Video Transcription

Video Summary

In this video, the speaker discusses the Xactech Vantage Total Ankle Implant, a low-profile ankle replacement option. The study aims to describe the early survivorship, reoperations, and revisions of the implant. The study included 190 patients with a minimum of two years follow-up. The demographics of the patients were typical for total ankle patients, with a majority having post-traumatic ankle arthritis. The results showed a 94.2% survivorship rate at final follow-up, with 10 revisions occurring at a mean of 1.5 years after primary surgery. Factors such as BMI, weight, hindfoot fusion, and preoperative coronal deformity were not significant risk factors for revision. The study also observed improvements in radiographic alignment and significant improvement in PROMIS scores in physical and pain-based domains. While the study had limitations due to its single institution focus and short follow-up, it provides valuable insights into the early performance of the Vantage implant. Further research is needed to determine optimal evaluation and treatment of peri-implant lucencies, as well as investigating the causes of early failures on the tibial side. (Credit: Speaker and AOFAS)

Asset Subtitle

Jensen K. Henry, MD, Lavan Rajan, BA, Robert Fuller, Elizabeth Cody, MD, Scott J. Ellis, MD, Jonathan T. Deland, MD, and Constantine A. Demetracopoulos, MD

Keywords

Xactech Vantage Total Ankle Implant

ankle replacement

early survivorship

reoperations

implant revisions